Amylyx Pharmaceuticals (AMLX) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition of avexitide aligns with a focus on high unmet medical needs in endocrine and neuroscience, targeting hyperinsulinemic hypoglycemia, especially PBH, and leveraging expertise in orphan diseases.

• Avexitide is a novel, first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation for PBH and congenital hyperinsulinism.

• Expands the pipeline beyond neurodegenerative diseases, building on experience from the Wolfram Syndrome program and other rare disease assets.

• Addresses sizable orphan indications with no approved therapies, including PBH, which affects about 160,000 people in the U.S.

Financial terms and conditions

• Acquisition cost was $35.1 million in cash, plus assumed liabilities and cure costs.

• Includes a 3% royalty on future avexitide sales in PBH, if approved.

• Patent protection extends through 2037, with potential for further extension and additional exclusivity.

• Amylyx had $373.3 million in cash, cash equivalents, and short-term investments as of March 31, 2024.

Synergies and expected cost savings

• Leverages existing commercial, clinical, and regulatory infrastructure and relationships with endocrinologists and rare disease experts.

• Enhances R&D capabilities and pipeline efficiency in rare endocrine and metabolic diseases.